Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

i-centre, randomized, placebo controlled, double-masked trials which will evaluate 125micro g of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion. The trials will enrol a total of approximately 320 patients each across approximately 40 centres in the United States (TG-MV-006) and 40 centres in Europe and North America (TG-MV-007). The safety review was the final of two safety reviews, and had been scheduled to take place after 50% of patients had been enrolled in one of the studies.

The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion within one month. Additional measures of efficacy and safety will also be assessed at various intervals over six months in both studies. It is estimated that these two studies will be completed by the end of 2010.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on the announcement said, "We are very pleased that the Phase III program for microplasmin is progressing well and that enrolment is on track. We remain confident that microplasmin could potentially make a significant difference to the treatment of back of the eye disease and we very much look forward to reporting the results from these trials."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... , July 2, 2015  Konica Minolta, Inc. (Konica ... that it has acquired Sawae Technologica Ltda., an X-ray ... Brazil , through its Brazilian healthcare sales company, ... Local Brazil market ... increasing population exceeding 200 million, significant healthcare technical advancements ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... treated with Satraplatin Demonstrated Statistically,Significant Improvement in ... March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion,Corporation and ... from,the double-blind, randomized satraplatin Phase 3 registrational,trial, ... Cancer) which were presented today at the ...
... Scientists,at WEHI have made a discovery with potentially ... undergoing,cancer chemotherapy. , The research team led by ... platelet life span is controlled by two key,molecules. ... new,drug to prolong the life span of platelets ...
Cached Medicine Technology:Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 2Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 3Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 4Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 5Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 6Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 7Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 2Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 3
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer Institute in ... one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just ... Researchers report that five mesothelioma patients treated with 25Gy of radiation over five days ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... the solar industry’s leading recognition of technical sales expertise from the North American ... Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established national ...
(Date:7/3/2015)... ... 03, 2015 , ... Scientists at several top US cancer centers believe they ... exposure. Click here to read the complete story , just posted on the ... Sinai Medical Center, and New York University exposed mice with a mutation on the ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... says will reveal biblical truth and expose popular lies regarding proper relationships according to ... Have Sex”, immediately goes into the core of the subject by explaining why certain ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... Health researchers have received nearly $13 million from the ... for victims of terrorist attacks, wartime use of toxic ... in these studies will be ,mustard gas, (sulfur mustard) ... is that they are designed to provide rescue treatments," ...
... -- In findings with major implications for the genetics of ... Center (BIDMC) and two other science teams in New York ... networks and showed how it may work to drive cancer ... 14 in the journal Cell describe aspects of ...
... times could cause men to seek more sexual partners, giving ... Gillath, a social psychology professor at the University of Kansas. ... when faced with a threatening environment, according to sexual selection ... think about their own death, which mimics conditions of "low ...
... a five year project with a $2 million ceiling ... the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined ... to prevent the acquisition of HIV and Herpes Simplex ... and acceptable, this combination of products would provide women ...
... (HealthDay News) -- Materialistic couples may have more money, ... a new study. Researchers have found that ... on couples, happiness and stability. In conducting the ... completed by more than 1,700 married couples across the ...
... have new avenues for scientific interaction, following a cooperation ... the government of Singapore. The agreement will allow Singapore ... It also means that EMBO workshops and lectures can ... agreement of its kind between EMBO, EMBC and Singapore. ...
Cached Medicine News:Health News:National Jewish Health researchers awarded $13 million to evaluate treatments for toxic gases 2Health News:Researchers discover hidden genetic influence on cancer 2Health News:Researchers discover hidden genetic influence on cancer 3Health News:Researchers discover hidden genetic influence on cancer 4Health News:Researchers discover hidden genetic influence on cancer 5Health News:Permanently dismal economy could prompt men to seek more sex partners 2Health News:USAID awards cooperative agreement to CONRAD for multipurpose prevention study 2Health News:Couples Can Pay a Price for Materialism 2Health News:Scientists in Singapore and Europe to collaborate 2
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Designated most popular model or size....
Designated most popular model or size. Double-ended. 2 mm wide....
Desmarres Retractor Size 4...
Medicine Products: